Experimental pharmacotherapy of cognitive impairment in Alzheimer's disease has seen a recent proliferation of drug trials involving a wide variety of drugs. Many of the earlier studies focused on cholinergic agents. However, subsequent advances in basic and biological sciences have broadened the scope of therapeutic strategies beyond the neurotransmitter approaches to include neurotrophic, metabolic-enhancing, membrane-modifying, and antitoxic agents, and have also provided rationale for developing antiamyloid and anti-infective therapies. For the clinician, it has not been easy to keep abreast of these developments. In this article, I present an overview of the cognition-enhancing drugs that have been used in the past, of those currently under investigation, and of new drugs and strategies that are likely to receive attention in the next few years.
Get full access to this article
View all access options for this article.
References
1.
1. Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons. JAMA1989; 262:2551–2556.
2.
2. Cooper JK. Drug treatment of Alzheimer's disease. Arch Int Med1991; 151:245–249.
3.
3. Maximizing Human Potential: Decade of the Brain 1990–2000. Subcommittee on Brain and Behavioral Sciences, Office of Science and Technology Policy. Washington, D.C.1991:37.
4.
4. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group. Neurology1984; 34:939–944.
5.
5. American Psychiatric Association: Diagnostic and statistical manual of mental disorders, 3rd Ed. - Rev.Washington, DC: American Psychiatric Association, 1987.
6.
6. Bowen DM, Smith CB, White P, et al. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain1976; 99:459–496.
7.
7. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet1976; ii:1403.
8.
8. Perry EK, Tomlinson BE, Blessed G, et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J1978; 2:1457–1459.
9.
9. Richter JA, Perry EK, Tomlinson BE. Acetylcholine and choline levels in postmortem brain tissue: preliminary observations in Alzheimer's disease. Life Sci1980; 26:1683–1689.
10.
10. Arendt T, Bigl V, Walther F, et al. Decreased ratio of CSF acetylcholinesterase to butyrylcholinesterase activity in Alzheimer's disease. Lancet1984; 1:173.
11.
11. Rylett RJ, Ball MJ, Colhoun EH. Evidence for high affinity choline transport in synaptosomes prepared from hippocampus and neocortex of patients with Alzheimer's disease. Brain Res1983: 289:169–175.
12.
12. Sims NR, Bowen DM, Smith CCT, et al. Glucose metabolism and acetylcholine synthesis in relation to neuronal activity in Alzheimer's disease. Lancet1980; 1:333–335.
13.
13. Whitehouse PJ, Price DL, Struble RG, et al. Alzheimer's disease and senile dementia. Loss of neurones in the basal forebrain. Science1982; 215:1237–1239.
14.
14. Blessed G, Tomlinson BE, Roth M.The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry1968; 114:797–811.
15.
15. Mash DC, Flynn DD, Potter LT. Loss of M2 muscarinic receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science1985; 228:1115–1117.
16.
16. Whitehouse PJ, Martino AM, Antuono PG, et al. Nicotinic acetylcholine binding in Alzheimer's disease. Brain Res1986; 371:146–151.
17.
17. Kitt CA, Price DL, Struble RG, et al. Evidence for cholinergic neurites in senile plaques. Science1984; 226:1443–1445.
18.
18. Mesulam M, Geula C, Moran MA. Anatomy of cholinesterase inhibition in Alzheimer's disease: effect of physostigmine and tetrahydroaminoacridine on plaque and tangles. Ann Neurol1987; 22:683–691.
19.
19. Patel SV, Tariot PN. Pharmacologic models of Alzheimer's disease. Psychiatr Clin North Am1991; 14:287–308.
20.
20. Bartus RT, Dean RL, Beer B, et al. The cholinergic hypothesis of geriatric memory dysfunction. Science1982; 217:408–417.
21.
21. Perry EK. The cholinergic hypothesis -10 years on. Br Med Bull186; 42:63–69.
22.
22. Pomara N, Domino EF, Yoon H, et al. Failure of single-dose lecithin to alter aspects of central cholinergic activity in Alzheimer's disease. J Clin Psychiatry1983; 44:293–295.
23.
23. Little A, Levy R, Chuaqui-Kidd C, et al. A double-blind, placebo-controlled trial of high dose lecithin in Alzheimer's disease. J Neurol Neurosurg Psychiatry185; 48:736–742.
24.
24. Etienne P, Dastoor D, Gauthier S, et al. Alzheimer's disease: lack of effect of lecithin treatment for 3 months. Neurology1981; 31:1552–1554.
25.
25. Thal LJ, Rosen W, Sharpless NS, et al. Choline chloride fails to improve cognition in Alzheimer's disease. Neurobiol Aging1981; 2:205–208.
26.
26. Etienne P, Gauthier S, Johnson G, et al. Clinical effects of choline in Alzheimer's disease. Lancet1978; 1:500–509.
27.
27. Thal LJ, Fuld PA, Masur DM, et al. Oral physostigmine and lecithin improve memory in Alzheimer disease. Ann Neurol1983; 13:491–196.
28.
28. Peters BH, Levin HS. Effects of physostigmine and lecithin on memory in Alzheimer disease. Ann Neurol1979; 6:219–221.
29.
29. Peters BH, Levin HS. Chronic oral physostigmine and lecithin administration in memory disorders of aging. In: Corkin J, ed. Aging: Alzheimer's disease - a report of progress. New York: Raven Press, 1982; 421–426.
30.
30. Wettstein A.No effect from double-blind trial of physostigmine and lecithin in Alzheimer disease. Ann Neurol1983; 13:210–212.
31.
31. Caine E.Cholinomimetic treatment fails to improve memory disorders. N Engl J Med1980; 303:585–586.
32.
32. Davidson M, Mohs RC, Hollander E, et al. Lecithin and piracetam in Alzheimer's disease. Biol Psychiatry1987; 22:112–113.
33.
33. Friedman E, Sherman KA, Ferris SH, et al. Clinical response to choline plus piracetam in senile dementia: relation to red cell choline levels. N Engl J Med1981; 304:1490–1491.
34.
34. Beller SA, Overall JE, Swann AC. Efficacy of oral physostigmine in primary degenerative dementia. Psychopharmacology1985; 87:147–151.
35.
35. Christie J, Shering A, Ferguson J, et al. Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia. Br J Psychiatry1981; 138:46–50.
36.
36. Muramoto O, Sugishita M, Ando K.Cholinergic system and constructional praxis: a further study of physostigmine in Alzheimer's disease. J Neurol Neurosurg Psychiatry1984; 47:485–491.
37.
37. Jotkowitz S.Lack of clinical efficacy of chronic oral physostigmine in Alzheimer's disease. Ann Neurology1983; 14:690–691.
38.
38. Thal LJ, Masur DM, Blau AD, et al. Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease. J Am Geriatr Soc1989; 37:42–48.
39.
39. Becker RE, Colliver J, Elble R, et al. Effects of metrifonate, a long-acting cholinesterase inhibitor. In: Alzheimer's disease: report of an open trial. Drug Dev Res1990; 19:425–434.
40.
40. Zhang SL. Therapeutic effects of huperzine A on the aged with memory impairment. New Drugs Clin Remedies1986; 5:260–262.
41.
41. Molloy DW, Cape RDT. Acute effects of oral pyridostigmine on memory and cognitive function in SDAT. Neurobiol Aging1989; 10:199–204.
42.
42. Thornton JE, Gershon S.The history of THA. In: Giacombini E, Becker R, eds. Current research in Alzheimer therapy. New York: Taylor and Francis, 1988.
43.
43. Palmieri DA, Butterfield DA. Effects of 9-amino-1,2,3,4-tetrahydroacridine (THA), a potential drug for treatment of Alzheimer's disease, on the physical state of human erythrocyte membranes. Prog Clin Biol Res1989; 292:419–424.
44.
44. Gauthier S, Massan H, Gauthier L, et al. Tetrahydroaminoacridine and lecithin in Alzheimer's disease. In: Giacombini E, Becker R, eds. Current research in Alzheimer's therapy. New York: Taylor and Francis, 1988:237–245.
45.
45. Summers W, Majovski V, Marsh G, et al. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer-type. N Engl J Med1986; 315:1241–1245.
46.
46. Tariot PN, Caine ED. Oral tetrahydroaminoacridine in the treatment of senile dementia, Alzheimer's type (letter). N Engl J Med1987; 316:1605.
47.
47. Pirozzolo FJ, Baskin DS, Swihart AA, et al. Oral tetrahydroaminoacridine in the treatment of senile dementia, Alzheimer's type (letter). N Engl J Med1987; 316:1603.
48.
48. Folstein MR, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res1975; 12:189–198.
49.
49. Gauthier S, Bouchard R, Lamontagne A, et al. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind crossover multicenter study. N Engl J Med1990; 322:1272–1276.
50.
50. Eagger SA, Levy R, Sahakian BJ. Tacrine in Alzheimer's disease. Lancet1991; 337:989–992.
51.
51. Jones RW. Tacrine in Alzheimer's disease (letter). Lancet1991; 337:1475–1476.
52.
52a. Chatellier G, Lacomblez L.Tacrine and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Br Med J1990; 300:495–499.
53.
52b. Davis KL, Thal LJ, Gamzu ER, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med1992; 327:1253–1259.
54.
52c. Farlow M, Gracon SI, Hershey LA, et al. A controlled trial of tacrine in Alzheimer's disease. JAMA1992; 268:253–259.
55.
53. Tariot PN, Cohen RM, Welkowitz JA, et al. Multiple-dose arecoline infusions in Alzheimer's disease. Arch Gen Psychiatry1988; 45:901–905.
56.
54. Newhouse PA, Sunderland T, Tariot PN, et al. Intravenous nicotine in Alzheimer's disease: a pilot study. Psychopharmacology1988; 95:171–175.
57.
55. Mouradian M, Mohr E, Williams J, et al. No response to high dose muscarinic agonist therapy in Alzheimer's disease. Neurology1988; 38:606–608.
58.
56. Davis K, Hollander E, Davidson M, et al. Induction of depression with oxotremorine in patients with Alzheimer's disease. Am J Psychiatry1987; 144:468–471.
59.
57. Harbaugh RE, Reeder TM, Senter HJ, et al. Intracerebroventricular bethanechol chloride infusion in Alzheimer's disease. J Neurosurg1989; 71:481–486.
60.
58. Penn RD, Martin EM, Wilson RS, et al. Intraventricular bethanechol infusion for Alzheimer's disease: results of double-blind and escalating trials. Neurology1988; 38:219–222.
61.
59. Davidson M, Zemishlany Z, Mohs RC, et al. 4-aminopyridine in the treatment of Alzheimer's disease. Biol Psychiatry1988; 23:485–490.
62.
60. Wesseling H, Agoston S, Van Dam GBP, et al. Effects of 4-aminopyridine in elderly patients with Alzheimer's disease. N Engl J Med1984; 310:988–989.
63.
61. Fisher A, Brandeis R, Karton I, et al. Rational treatment strategy for Alzheimer's disease: recent advances. Advs Neurol1990; 51:257–259.
64.
62. Bondareff W, Moutjoy CQ, Roth M.Selective loss of neurones of origin of adrenergic projection to cerebral cortex (nucleus locus coernleus) in senile dementia. Lancet1981; 1:783–784.
65.
63. Adolfsson R, Gottfries CG, Oreland L, et al. Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer type. Life Sci1980; 17:1029–1034.
66.
64. Cross AJ, Crow TJ, Perry EK, et al. Reduced dopamine-beta-hydroxylase activity in Alzheimer's disease. Br Med J1981; 282:93–94.
67.
65. Gottfries CQ, Adolfsson R, Aquilonius SM, et al. Biochemical changes in dementia disorders of Alzheimer type. Neurobiol Aging1983; 4:261–271.
68.
66. Perry EK, Tomlinson BE, Blessed G, et al. Neuropathological and biochemical observations on the noradrenergic system in Alzheimer's disease. J Neurol Sci1981; 51:279–287.
69.
67. Tariot PN, Cohen RM, Sunderland T, et al. L-deprenyl in Alzheimer's disease: preliminary evidence for behavioral change with monoamine oxidase B inhibition. Arch Gen Psychiatry1987; 44:427–433.
70.
68. Mangoni A, Grassi MD, Frattola L, et al. Effects of a MAO-B inhibitor in the treatment of Alzheimer disease. Eur Neurol1991; 31:100–107.
71.
69. Piccinin GL, Finali G, Piccirilli M.Neuropsychological effects of L-deprenyl in Alzheimer's type dementia. Clin Neuropharmacol1990; 13:147–163.
72.
70. Agnoli A, Martucci N, Fabrini G, et al. Monoamine oxidase and dementia: treatment with an inhibitor of MAO-B activity. Dementia1990; 1:109–114.
73.
71. Monteverde A, Gnemmi P, Rossi F, et al. Selegiline in the treatment of mild to moderate Alzheimer-type dementia. Clin Therap1990; 12:315–322.
74.
72. Curcio CA, Kemper T.Nucleus raphe dorsalis in dementia of the Alzheimer type: neurofibrillary changes and neuronal packing density. J Neuropathol Exp Neurol1984; 43:359–368.
75.
73. Bowen DM, Allen SJ, Benton JS, et al. Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease. J Neurochem1983; 41:266–272.
76.
74. Reynolds GP, Arnold L, Rossor MN, et al. Reduced binding of [3H] ketanserin to cortical 5-HT receptors in senile dementia of the Alzheimer type. Neurosci Lett1984; 44:47–51.
77.
75. Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: a Nordic multicentre study. Br J Psychiatry1990; 157:894–901.
78.
76. Greenwald BS, Marin DB, Silverman SM. Serotoninergic treatment of screaming and banging in dementia. Lancet1986; 2:1464–1465.
79.
77. Dehlin O, Hedenrud B, Jansson P, et al. A double-blind comparison of alapractolate and placebo in the treatment of patients with senile dementia. Acta Psychiatry Scand1985; 71:190–196.
80.
78. Lawlor BA, Sunderland T, Mellow AM, et al. Hyperresponsivity to the serotonin agonist M-chlorphenylpiperazine in Alzheimer's disease: a controlled study. Arch Gen Psychiatry1989; 46:542–549.
81.
79. Handelmann GA, Nevins ME, Mueller LL, et al. Milacemide, a glycine prodrug, enhances performance of learning tasks in normal and amnestic rodents. Pharmacol Biochem Behav1989; 34:823–828.
82.
80. Mohr E, Bruno G, Foster N, et al. GABA-agonist therapy for Alzheimer's disease. Clin Neuropharmacol1986; 9:257–263.
83.
81. Reifler BV, Teri L, Raskind M, et al. Double-blind trial of imipramine in Alzheimer's disease patients with and without depression. Am J Psychiatry1989; 146:45–49.
84.
82. Passeri M, Cucinotta D, DeMello M, et al. Minaprine for senile dementia. Lancet 1985; i:824.
85.
83. Francis PT, Bowen DM, Lowe SL, et al. Somatostatin content and release measured in cerebral biopsies from demented patients. J Neurol Sci1987; 78:1–16.
86.
84. Beal MF. Somatostatin alterations in CNS in neurological diseases. In: Martin J, Barchas J, eds. Neuropeptides in neurological and psychiatric disease. New York: Raven Press, 1986.
87.
85. Soininen HS, Jolkkonen JT, Reinikainen KH, et al. Reduced cholinesterase activity and somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with dementia of the Alzheimer type. J Neurol Sci1984; 63:167–172.
88.
86. Morrison JH, Rogers J, Scherr S, et al. Somatostatin immunoreactivity in neuritic plaques of Alzheimer patients. Nature1985; 314:90–92.
89.
87. Roberts GW, Crow TJ, Polak JM. Location of neuronal tangles in somatostatin neurones in Alzheimer's disease. Nature1985; 314:92–94.
90.
88. Cutler NR, Haxby J, Narang PK, et al. Evaluation of an analog of somatostatin (L363, 586) in Alzheimer's disease. New Engl J Med1985; 312:725.
91.
89. Yarbrough GG. Thyrotropin-releasing hormone and CNS cholinergic neurons. Life Sci1983; 33:111–118.
92.
90. Van Ree JM, Bohus B, Versteeg DHG, et al. Neurohypophyseal principles and memory processes. Biochem Pharmacol1978; 27:1793–1800.
93.
91. Bartus RT, Dean RL, Beer B.Neuropeptide effects on memory in aged monkeys. Neurobiol Aging1982; 3:61–68.
94.
92. Soininen H, Koskinen C, Helkala E, et al. Treatment of Alzheimer's disease with a synthetic ACTH 4–9 analog. Neurology1985; 35:1348–1351.
95.
93. Jolkkonen JT, Soininen HS, Riekkinen PJ. The effect of ACTH 4–9 analog (ORG 2766) on some cerebrospinal fluid parameters in patients with Alzheimer's disease. Life Sci1985; 37:585–590.
96.
94. Mazurek MF, Beal MF, Bird ED, et al. Vasopressin in Alzheimer's disease: a study of postmortem brain concentrations. Ann Neurol1986; 20:665–670.
97.
95. Raskind MA, Peskind ER, Lampe TH, et al. Cerebrospinal fluid vasopressin, oxytocin, somatostatin, and B-endorphin in Alzheimer's disease. Arch Gen Psychiatry1986; 43: 382–388.
98.
96. Peabody CA, Davies H, Berger PA, et al. Desamino-d-arginine-vasopressin (DDAVP) in Alzheimer's disease. Neurobiol Aging1986; 7:301–303.
99.
97. Wolters EC, Riekkinen P, Lowenthal A, et al. DGAVP (Org 5667) in early Alzheimer's disease patients: an international double-bind, placebo-controlled, multicenter trial. Neurology1990; 40:1099–1101.
100.
98. Horita A, Carino MA, Lai H.Pharmacology of thyrotropin-releasing hormone. Annu Rev Pharmacol Toxicol1986; 26:311–332.
101.
99. Molchan SE, Mellow AM, Lawlor BA, et al. TRH attenuates scopolamine-induced memory impairment in humans. Psychopharmacology1990; 100:84–89.
102.
100. Mellow AM, Sunderland T, Cohen RM, et al. Acute effects of high-dose thyrotropin releasing hormone infusions in Alzheimer's disease. Psychopharmacology1989; 98:403–407.
103.
101. Lampe TH, Norris J, Risse SC, et al. Therapeutic potential of thyrotropin-releasing hormone and lecithin co-administration in Alzheimer's disease. In: Iqbal K, McLachlan DRC, Winblad B, Wisniewski HM, eds. Alzheimer's disease: basic mechanisms, diagnosis and therapeutic strategies. Chichester, England: John Wiley and Sons Ltd., 1990.
104.
102. Fillit H, Weinreb H, Cholst I, et al. Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. Psychoneuroendocrinology1986; 11:337–345.
105.
103. Tariot PN, Sunderland T, Weingartner H, et al. Naloxone and Alzheimer's disease: cognitive and behavioral effects of a range of doses. Arch Gen Psychiatry1986; 43:727–732.
106.
104. Henderson VW, Roberts E, Wimer C, et al. Multicenter trial of naloxone in Alzheimer's disease. Ann Neurol1989; 25:404–406.
107.
105. Hyman BT, Eslinger PJ, Damasio AR. Effect of naltrexone on senile dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry1985; 48:1169–1171.
108.
106. Weiss BL. Failure of nalmefene and estrogen to improve memory in Alzheimer's disease. Am J Psychiatry1987; 144:386–387.
109.
107. Facci L, Leon A, Toffano G, et al. Promotion of neuritogenesis in mouse neuroblastoma cells by exogenous ganglio-sides. Relationship between the effect and the cell association of ganglioside GM1. J Neurochem1984; 42:299–305.
110.
108. Ala T, Romero S, Knight F, et al. GM-1 treatment of Alzheimer's disease: a pilot study of safety and efficacy. Arch Neurol1990; 47:1126–1130.
110. Thoenen H, Edgar D.Neurotrophic factors. Science1985; 229:238–242.
113.
111. Hefti F, Hartikka J, Salvatierra A, et al. Localization of nerve growth factor receptors in cholinergic neurons of the human basal forebrain. Neurosci Lett1986; 69:37–41.
114.
112. Mobley WC, Rutkowski JL, Tennekoon GL, et al. Choline acetyltransferase activity in striatum of neonatal rats increased by nerve growth factor. Science1985; 229:284–287.
115.
113. Gnahn H, Hefti F, Heumann R, et al. NGF-mediated increase of choline acetyltransferase (ChAT) in the neonatal rat fore-brain: evidence for a physiological role of NGF in the brain?Dev Brain Res1983; 9:45–52.
116.
114. Harbaugh RE. Nerve growth factor as a potential treatment in Alzheimer's disease. Biomed Pharmacother1989; 43:483–485.
117.
115. Reisberg B, Ferris SH, Gershon S.An overview of pharmacologic treatment of cognitive decline in the aged. Am J Psychiatry1981; 138:593–600.
118.
116. Hollister LE, Yesavage J.Ergoloid mesylates for senile dementia: unanswered questions. Ann Intern Med1984; 100:894–898.
119.
117. Spiegel R, Huber F, Koberle S.A controlled long-term study with ergoloid mesylates (hydergine) in healthy, elderly volunteers. J Am Geriatr Soc1983; 31:549–555.
120.
118. Loew DM, Weil C.Hydergine in senile mental impairment. Gerontology1982; 28:54–74.
121.
119. McDonald RJ. A review of 26 clinical studies. Pharmacopsychiatry1979; 12:407–422.
122.
120. Hughes JR, Williams JG, Currier RD. An ergot alkaloid preparation (hydergine) in the treatment of dementia: critical review of the clinical literature. J Am Geriatr Soc1976; 24:490–497.
123.
121. Thompson T, Filley C, Mitchell D, et al. Lack of efficacy of hydergine in patients with Alzheimer's disease. N Engl J Med1990; 323:445–448.
124.
122. Thienhaus O, Wheeler B, Simon S, et al. A controlled double-blind study of high dose dihydroergotoxine mesylate (hydergine) in mild dementia. J Am Geriatr Soc1987; 35:219–223.
125.
123. VanLoveran-Huyben CMS, Engelaar HFWJ, Hermans MBM, et al. Double-blind clinical and physiologic study of ergoloid mesylates in subjects with senile mental deterioration. J Am Geriatr Soc1984; 32:584–588.
126.
124. Bertoni-Freddari C, Giuli C, Pieri C, et al. The effect of chronic hydergine treatment on the plasticity of synaptic junctions in the dentate gyrus of aged rats. J Gerontol1987; 42:482–486.
127.
125. Battaglia A, Bruni G, Ardia A, et al. Nicergoline in mild to moderate dementia: a multicenter, double-blind, placebo-controlled study. J Am Geriatr Soc1989; 37:295–302.
128.
126. Funk KF, Schmidt J.Changes of dopamine metabolism by hypoxia and effect of nootropic drugs. Biomed Biochem Acta1984; 11:1301–1304.
128. Spignoli G, Pepeu G.Interactions between oxiracetam, aniracetam and scopolamine on behavior and brain acetylcholine. Pharmacol Biochem Behav1987; 27:491–495.
131.
129. Ferris SH, Reisberg B, Crook T, et al. Pharmacologic treatment of senile dementia: choline, 1-dopa, piracetam, and choline plus piracetam. In: Corkin S, ed. Aging, Vol. 19. Alzheimer's disease: a report of progress. New York: Raven Press, 1982:475–481.
132.
130. Sourander L, Portin R, Molsa P, et al. Senile dementia of the Alzheimer-type treated with aniracetam: a new nootropic agent. Psychopharmacology1987; 91:90–95.
133.
131. Saletu B, Linzmayer L, Grunberger J, e al. Double-blind, placebo-controlled, clinical, psychometric and neurophysiological investigations with oxiracetam in the organic brain syndrome of late life. Neuropsychobiology1985; 13:44–52.
134.
132. DeNoble VJ. Vinpocetine enhances retrieval of a step-through passive avoidance response in rats. Pharmacol Biochem Behav1987; 26:83–86.
135.
133. Thal LJ, Salmon DP, Lasker B, et al. The safety and lack of efficacy of vinpocetine in Alzheimer's disease. J Am Geriatr Soc1989; 37:515–520.
136.
134. Mehraein P, Yamada M, Tarnowska-Dziduszkio E.Quantitative study of dendrites and dendritic spines in Alzheimer's disease and senile dementia. In: Kreutzberg GW, ed. Advances in Neurology, Vol. 12. Physiology and pathology of dendrites. New York: Raven Press, 1975.
137.
135. Rouser G, Kritchevsky G, Yamamoto A, et al. Lipids in the nervous system of different species as a function of age: brain, spinal cord peripheral nerve, purified whole cell preparations and subcellular particulates: regulatory mechanisms and membrane structure. Adv Lipid Res1972; 10:261–360.
138.
136. Amaducci L, Smid Group. Phosphatidylserine in the treatment of Alzheimer's disease: results of a multicenter study. Psychopharmacol Bull1988; 24:130–134.
139.
137. Cohen B, Satlin A, Zubenko G.S-adenosyl-l-methionine in the treatment of Alzheimer's disease. J Clin Psychopharmacol1988; 8:43–47.
140.
138. Yankner BA, Dawes LR, Fisher S, et al. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science1989; 245:417–420.
141.
139. Saper CB, German DC, White CL. Neuronal pathology in the nucleus basalis and associated cell groups in senile dementia of the Alzheimer's type: possible role in cell loss. Neurology1985; 35:1089–1905.
142.
140. Caputo CB, Salama AI. The amyloid proteins of Alzheimer's disease as potential targets for drug therapy. Neurobiol Aging1989; 10:451–461.
143.
141. Kruck TPA, Crapper-McLachlan DR. Aluminum as a pathogenetic factor in senile dementia of the Alzheimer type: ion specific chelation. Alzheimer's disease and related disorders. In: Iqbal K, ed. Progress in clinical and biological research, Vol. 31. New York: Alan R. Liss, 1989:1155–1167.
144.
142. Crapper-McLachlan DR. Aluminum and Alzheimer's disease. Neurobiol Aging1986; 7:525–532.
145.
143. Trapp GA, Miner GD, Zimmerman RL, et al. Aluminum levels in brain in Alzheimer's disease. Biol Psychol1978; 13:709–718.
146.
144. Crapper DR, Krishnan SS, Dalton AJ. Brian aluminum in Alzheimer's disease and experimental neurofibrillary degeneration. Science1973; 180:511–513.
147.
145. Martyn CN, Osmond C, Edwardson JA, et al. Geographical relation between Alzheimer's disease and aluminum in drinking water. Lancet1989; 1:59–62.
148.
146. Flaten TP. Geographical association between aluminum in drinking water and registered death rates with dementia including Alzheimer's disease in Norway. Proceedings of the Second International Symposium on Geochemistry and Health; London, England 1987:22–24.
149.
147. McLachlan DR, Dalton AJ, Kruck TPA, et al. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet1991; 337:1304–1308.
150.
148. Cardelli M, Russell M, Bagne C, et al. Chelation therapy: unproved modality in the treatment of Alzheimer-type dementia. J Am Geriatr Soc1985; 33:548–551.
151.
149. McDermott JR, Smith IA, Iqbal K, et al. Brain aluminum in aging and Alzheimer's disease. Neurology1979; 29: 809–814.
152.
150. Spencer P, Nunn P, Hugon J, et al. Guam amyatrophic lateral sclerosis - Parkinsonion dementia linked to a plant excitatoxin. Science1987; 237:517–522.
153.
151. Schanne FAK, Kane AB, Young EE. Calcium dependence of toxic cell death: a final common path. Science1979; 206:700–702.
154.
152. Deary IJ, Hendrickson AE, Burns A.Serum calcium levels in Alzheimer's disease: a finding and an aetiological hypothesis. Person Individ Diff (Pegamon J)1987; 8:75–80.
155.
153. Selkoe DJ, Abraham C, Ihara Y.Brain transglutaminase: in vitro cross linking of human neurofilament proteins into insoluble polymers. Proc Natl Acad Sci USA1982; 79:6070–6074.
156.
154. Garruto RM, Fukatsu R, Yanagihara R, et al. Imaging of calcium and aluminum in neurofibrillary tangle-bearing neurons in parkinsonism - dementia of Guam. Proc Natl Acad Sci USA1984; 81:1875–1879.
157.
155. Tollefson GD. Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia. Biol Psychiatry1990; 27: 1133–1142.
158.
156. Rogers RL, Meyers JS, Mortel KF, et al. Decreased cerebral blood flow precedes multi-infarct dementia but follows senile dementia of Alzheimer type. Neurology1986; 36:1–6.
159.
157a. Prusiner SB. Prions. Scientific American1984; 251:48–57.
160.
157b. Mozar H, Bal D, Howard D.Perspectives on the etiology of Alzheimer's disease. JAMA1987; 257:1503–1507.
161.
158. McGeer PL, McGeer E, Rogers J, et al. Anti-inflammatory drugs and Alzheimer disease. Lancet1990; 335:1037.
162.
159. Kushnir SL, Ratner JT, Gregoire PA. Multiple nutrients in the treatment of Alzheimer's disease. J Am Geriatr Soc1987; 35:476–477.
163.
160. Kristensen V, Olsen M, Theilgaard A.Levodopa treatment of presenile dementia. Acta Psychiatry Scand1984; 70: 470–477.
164.
161. Tariot PN, Sunderland T, Cohen RM, et al. Tranylcypromine compared with L-deprenyl in Alzheimer's disease. J Clin Psychopharm1988; 8:23–27.
165.
162. Mohr E, Schlegal J, Fabbrini G, et al. Clonidine treatment of Alzheimer's disease. Arch Neurol1989; 46:376–378.
166.
163. Schlegel J, Mohr E, Williams J, et al. Guanfacine treatment of Alzheimer's disease. Clin Neuropharmacol1989; 12:124–128.
167.
164. Schubert H, Fleischhacker W.Therapeutische Ansatz ba Dementiellen Syndromen. Ergebnisse mit Amantadin-Sulfat unter Stationaren Bedingungen. Arztl Praxis1979; 46:2157–2160.
168.
165. Phuapradit P, Phillips M, Lees AJ, et al. Bromocriptine in presenile dementia. Br Med J1978; 1:1052–1053.
169.
166. Fleischacker W, Buchgeher A, Schubert H.Memantine in the treatment of senile dementia of the Alzheimer-type. Prog Neuropsychopharmacol Biol Psychiatry1986; 10:87–93.
170.
167. Smith D, Stromgren E, Peterson H, et al. Lack of effect of tryptophan treatment in demented gerontopsychiatric patients. Acta Psychiatry Scand1984; 70:470–477.
171.
168. Cutler NR, Haxby J, Kay AD, et al. Evaluation of zimeldine in Alzheimer's disease. Cognitive and biochemical measures. Arch Neurol1985; 42:744–748.
172.
169. Bernard A, Goffart JM. A double-blind cross-over clinical evaluation of cinnarizine. Clinical Trials Journal1968; 5:945–948.
173.
170. Capote B, Parikh N.Cyclandelate in the treatment of senility: a controlled study. J Am Geriatr Soc1978; 26:360–362.
174.
171. Affleck DC, Treptow KR, Herrick HD. The effects of isox-suprine hydrochloride (Vasodilan) on chronic cerebral arteriosclerosis. J Nerv Ment Dis1961; 132:335–338.
175.
172. Judge TG, Urquhart A.Naftidofuryl—a double-blind cross-over study in the elderly. Curr Med Res Opin1972; 1:166–172.
176.
173. Branconnier RJ, Cole JO. Effects of chronic papaverine administration on mild senile organic brain syndrome. J Am Geriatr Soc1977; 25:458–462.
177.
174. Knezevic S, Mubrin Z, Risberg J, et al. Pyrintol treatment of SDAT patients: evaluation by psychiatric and neurological examination, psychometric testing, and rCBF measurements. Int Clin Psychopharmacol1989; 4:25–38.
178.
175. Walsh AC, Walsh BH, Melaney C.Senile-presenile dementia: follow-up on an effective psychotherapy-anticoagulant regimen. J Am Geriatr Soc1978; 26:467–470.
179.
176. Harwart D.The treatment of chronic cerebrovascular insufficiency A double-blind study with pentoxifylline (Trental 400). Curr Med Res Opin1979; 6:73–84.
180.
177. Thompson LW, Davis GC, Obrist WD, et al. Effects of hyperbaric oxygen on behavioral and physiologic measures in elderly demented patients. J Gerontol1976; 31:23–28.
179. Shimamoto T, Murase H, Numano F.Treatment of senile dementia and cerebellar disorders with phatalazinol. Cyclic AMP-increasing agent, phthalazinol in therapeutic trials in hitherto incurable morbid conditions. Mech Ageing Dev1976; 5:241–250.
183.
180. Rai G, Wright G, Scott L, et al. Double-blind, placebo-controlled study of acetyl-l-carnitine in patients with Alzheimer's disease. Curr Med Res Opin1990; 11:638–647.
184.
181. Blass JPGleason P, Brush D, et al. Thiamine and Alzheimer's disease: a pilot study. Arch Neurol1988; 45:833–835.
185.
182. Brinkman SD, Pomara N, Barnett N, et al. Lithium-induced increases in red blood cell choline and memory performance in Alzheimer-type dementia. Biol Psychiatry1984; 19:157–164.
186.
183. Parker W, Filley C, Parks J.Cytochrome oxidase deficiency in Alzheimer's disease. Neurology1990; 40:1302–1303.
187.
184. Blass JBaker A, Ko L, et al. Induction of Alzheimer antigens by an uncoupler of oxidative phosphosylation. Arch Neurol1990; 47:864–869.
